Results 181 to 190 of about 40,676 (197)

The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping

Cancer Treatment Reviews, 2020
Ravi Salgia, Martin Sattler, Enriqueta Felip   +2 more
exaly  

Exon Skipping

2008
openaire   +1 more source

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

Lancet, The, 2011
Sebahattin Cirak, V Arechavala-Gomeza, Karen Anthony   +2 more
exaly  

Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy

Molecular Therapy, 2017
Yusuke Echigoya, Kenji Rowel Q Lim, James S Novak   +2 more
exaly  

Targeted Exon Skipping in Transgenic hDMD Mice: A Model for Direct Preclinical Screening of Human-Specific Antisense Oligonucleotides

Molecular Therapy, 2004
Annemieke Aartsma-Rus, Johan T Den Dunnen   +1 more
exaly  

Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA

Nature Genetics, 1993
Garry R Cutting
exaly  

Exon skipping therapy for DMD.

Journal of neuromuscular diseases, 2022
openaire   +1 more source

Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse

Nature Medicine, 2003
Christopher J Mann, Susan Fletcher
exaly  

Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model Neonates

Molecular Therapy, 2019
Kenji Rowel Q Lim, Yusuke Echigoya, Tetsuya Nagata   +2 more
exaly  

Exon-skipping therapy for Duchenne muscular dystrophy – Authors' reply

Lancet, The, 2012
V Arechavala-Gomeza, Sebahattin Cirak, Karen Anthony   +2 more
exaly